Al-Nakib W, Tyrrell D A
MRC Common Cold Unit, Harvard Hospital, Salisbury, Wiltshire, U.K.
Antiviral Res. 1987 Nov;8(4):179-87. doi: 10.1016/0166-3542(87)90072-6.
A 'new' generation of synthetic antirhinovirus compounds has recently become available for in vitro evaluation. Thus a new group of compounds from Janssen was found to be 10-fold more active than enviroxime or 57-fold more active than dichloroflavan (DCF), against human rhinovirus 9 (HRV-9). In addition, they were also some 5- and 10-fold more potent than enviroxime and DCF, respectively, against HRV-2. Similarly, a 'new' series of antirhinovirus compounds from Roche, although as active as enviroxime against HRV-9, were found to be 4-fold more potent than DCF against the same virus. Moreover, they were 45- and 90-fold more active than enviroxime and DCF, respectively, when tested against HRV-2. We found that generally HRV-2 was more sensitive to these new compounds than HRV-9. In this study we also report on the synergistic interaction between these new synthetic substances and also with some of the earlier compounds such as DCF and enviroxime and we discuss the possible implication of this synergistic activity regarding the future prevention and treatment of common colds caused by rhinoviruses.
新一代合成抗鼻病毒化合物最近已可用于体外评估。因此，发现杨森公司的一组新化合物对人鼻病毒9（HRV - 9）的活性比恩韦肟高10倍，比二氯黄烷（DCF）高57倍。此外，它们对HRV - 2的效力分别比恩韦肟和DCF约高5倍和10倍。同样，罗氏公司的一系列“新”抗鼻病毒化合物，虽然对HRV - 9的活性与恩韦肟相同，但发现对同一病毒的效力比DCF高4倍。此外，在针对HRV - 2进行测试时，它们的活性分别比恩韦肟和DCF高45倍和90倍。我们发现，一般来说，HRV - 2对这些新化合物比HRV - 9更敏感。在本研究中，我们还报告了这些新合成物质之间以及与一些早期化合物（如DCF和恩韦肟）之间的协同相互作用，并讨论了这种协同活性对未来预防和治疗由鼻病毒引起的普通感冒的可能意义。
